View Older Stories View More Recent Stories

Jan 25, 2022 06:00AM eFFECTOR's (EFTR) tomi Cohorts Unlikely to Be Positive, Stock is a High Risk, Downgrade to Hold, Cut PT to $6.20 - Stifel
Jan 25, 2022 05:46AM Eli Lilly's (LLY) tirzepatide Has Multi-Billion Opportunities Outside of Diabetes, Currently Undervalued - Cantor Fitzgerald
Jan 24, 2022 07:51AM Clinical Hold of Viking's (VKTX) VK0214 Trial is Immaterial, Bull Thesis is Based on VK2809 in NASH, Buy the Weakness - Truist Securities
Jan 24, 2022 06:27AM No Fundamental Reason of I-Mab's (IMAB) Weakness, Risk-Reward is to The Upside - Cantor Fitzgerald
Jan 24, 2022 06:24AM Johnson & Johnson's (JNJ) Potential to Change Multiple Myeloma Treatment Paradigm in Underappreciated, Stock Remains Top Pick - Cantor Fitzgerald
Jan 21, 2022 05:38AM Veru (VERU) Remains a Top Pick, POC Data Fuels Optimism for Upcoming Phase 3 Readout - Oppenheimer
Jan 20, 2022 04:21PM Arcutis Biotherapeutics' (ARQT) Pipeline is Strong and Diversified, roflumilast cream Has High Approval Chance, Multiple Catalysts to Look Forward to - Mizuho
Jan 20, 2022 09:19AM Frank Clyburn's Departure is Merck's (MRK) CEO's Opportunity to Build Out a Leadership Team Directly, Reiterate Buy - Mizuho
Jan 19, 2022 08:29AM EU Approval of Tavneos Likely to Add Positive Tailwind to Shares of ChemoCentryx (CCXI) - Stifel
Jan 19, 2022 07:28AM Regeneron Pharma's (REGN) Latest Dupixent Data Can Add $12/sh, Drug Peak Sales are $14B Across All Indications - Truist Securities
Jan 19, 2022 07:14AM Bicycle Therapeutics Plc (BCYC), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE) - Needham's Favorite 2022 Biotech Picks
Jan 19, 2022 05:46AM Despite Prior Hiccups, Revance Therapeutic (RVNC) Could Launch DAXlin in Early 2023 - William Blair
Jan 18, 2022 08:55AM Axsome Therapeutics' (AXSM) Recent FDA Communications Are Encouraging Signs of Progress, Reiterate Overweight - Cowen
Jan 18, 2022 06:15AM Sage Therapeutics' (SAGE) CORAL Phase 3 Study Likely to Meet Primary Endpoint, But Not Enough to Drive Stock Higher - Needham & Company
Jan 18, 2022 06:13AM Arcutis Biotherapeutics (ARQT) Has Favorable Risk/Reward, Multiple Catalysts to Look Up to - Mizuho Securities
Jan 18, 2022 05:56AM Incyte's (INCY) OPZELURA Launch in Line with Expectations - Mizuho
Jan 14, 2022 11:32AM Cytokinetics (CYTK) Has $2-$4 Upside on Upcoming CK-274 Data Readout, None of It Priced In, Data as Early as Next Week - Mizuho
Jan 14, 2022 11:03AM Peloton (PTON) is Less Bearish Than Stock's Performance Suggests, Medium/Long Term Outlook Remains Bright - Analysts
Jan 14, 2022 07:20AM Axsome Therapeutics's (AXSM) AXS-05 Probability of Success Lowered Following Mgmt Chat, PT Shashed to $90 - Truist Securities
Jan 14, 2022 05:41AM Pfizer (PFE) PT Raised to $76 at BMO Capital, Reiterated as Top Pick, COVID 2022 Revenue Estimates Hiked to $63B from $40B
Jan 13, 2022 04:50PM Gilead (GILD) Reiterates Confidence on Hitting PFS Improvement in HR+/HER2- Trial - BMO Capital Markets
Jan 13, 2022 02:23PM Harmony Biosciences' (HRMY) Wakix Continues to Grow, More Upside Possible Should Pandemic Lift - Needham & Company
Jan 13, 2022 08:12AM VYNE Therapeutics (VYNE) MST Sale is Good news, Underscores Company's Ability to Execute - Cantor Fitzgerald
Jan 13, 2022 05:55AM Editas Medicine (EDIT) Shares Can be Volatile Given Imminent Competitor's Data - Stifel
Jan 13, 2022 05:51AM Arcus Biosciences' (RCUS) Research Engine Continues to be Productive, Management Executes on Clinical Strategy - Truist
Jan 12, 2022 03:10PM Equillium (EQ) Stock Could See Upside into Mid-2022 Data Readouts - Stifel
Jan 12, 2022 10:52AM Long-Term Data May Add Momentum Behind Applied Genetic's (AGTC) AGTC-501 - Stifel
Jan 12, 2022 06:46AM Biogen's (BIIB) Aduhelm Access Will be Significantly Limited, Company's Future Rests on lecanemab Data - Analysts
Jan 12, 2022 06:24AM Heron Therapeutics (HRTX) and Omeros (OMER) Top Cantor Fitzgerald's Most Shorted List
Jan 12, 2022 06:21AM Strong Early Momentum for LIVMARLI Sets Stage for Active 2022 for Mirum Pharamceuticals (MIRM) - H.C. Wainwright
Jan 12, 2022 06:14AM Scientific Merits of Verve Therapeutics' (VERV) PCSK9 Exist, but Worries on Commercial Appeal Remain - Stifel
Jan 12, 2022 06:11AM Continued Optimism for Alnylam Pharmaceuticals' (ALNY) Apollo-B Success - Oppenheimer
Jan 12, 2022 06:07AM 2022 Could Turn the Corner for Orchard Therapeutics Plc (ORTX), Its Programs Could Receive Regulatory Approval - Stifel
Jan 11, 2022 03:21PM Rocket Pharmaceuticals (RCKT) is Top Pick, Can Begin to Reclaim Lost Value, Earlier Commercialization is Not Ruled Out - Stifel
Jan 11, 2022 06:54AM Avadel Pharma's (AVDL) FT218 is Approvable, But Timeline Remains Unclear - Needham & Company
Jan 11, 2022 06:49AM Positive View of Amicus Therapeutics (FOLD) Remains, Despite Lower Guidance - Needham & Company
Jan 11, 2022 06:44AM Doubling of BioCryst's (BCRX) Orladeyo Sales Feasible in 2022, but Competition Will Weigh In Down the Road - Needham
Jan 10, 2022 02:30PM Sarepta Therapeutics' (SRPT) Now Has Clear Path for SRP-9001's Regulatory Submission; Gene Therapy Pipeline Will Generate Up to $800M in 2022 - William Blair
Jan 10, 2022 02:18PM Sparsentan Is Main Driver of Travere Therapeutics (TVTX) Stock, Progress On the Drug is Encouraging, Product Should Ultimately be Approved - William Blair
Jan 10, 2022 01:34PM Collaboration with Merck (MRK) is a Positive for Neoleukin Therapeutics (NLTX), Creates Additional Monotherapy Opportunity - Stifel
Jan 10, 2022 09:32AM Catalyst Pharmaceuticals (CPRX) Litigation News Are Welcoming, Expect CPRX Stock Momentum to Continue in 2022 - Truist
Jan 10, 2022 09:16AM Prelim Revenues Indicate Continued Strength in Ultragenyx Pharma's (RARE) Base Business, Provide Optimism for 2022 - Stifel
Jan 10, 2022 09:10AM Clinical Hold Removal is Positive for Allogene Therapeutics (ALLO), but ASH 2021 Update May Weigh on Shares - Stifel
Jan 10, 2022 08:40AM Encoraging to See Progress Made by Humanigen Inc. (HGEN), but More Visibility Needed - H.C. Wainwright
Jan 10, 2022 06:40AM Revance Therapeutics' (RVNC) Remains on Track to Submit Daxi BLA in 1H22 and get New PDUFA in 2H22 - Needham
Jan 10, 2022 06:37AM Liquidia Technologies (LQDA) CEO Change and Litigation Developments Improve Outlook - Needham
Jan 10, 2022 06:29AM Beam Therapeutics Inc. (BEAM) and Pfizer (PFE) Deal May Rapidly Re-risk and Unlock Beam's Value - Stifel
Jan 7, 2022 11:12AM Ultragenyx Pharma (RARE) Collaboration with Regeneron (REGN) is Intriguing, But Own Pipeline Progress Remains Key - Stifel
Jan 7, 2022 09:45AM Atea Pharmaceuticals' (AVIR) Continues to Have a Significant Market in COVID Response, Despite Data Setbacks - William Blair
Jan 7, 2022 09:08AM Absci (ABSI) and Merck's (MRK) AI Collaboration is an Early, but Intriguing Investment - Truist
View More Recent Stories View Older Stories